46 recruiting. 46 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 46 | Recruiting 46 |
| Phase 2 | 5 | Recruiting 5 |
Follow Anemia: new trials by email Literature Review of Anemia trials Research Report on Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Therapy With Danazol, Prednisolone, and Thalidomide for Thalidomide-Refractory Transfusion-Dependent β-Thalassemia Thalidomide, Danazol, Prednisolone - Beta-Thalassemia, Thalassemia | Phase 3 | Recruiting | Khyber Medical University Peshawar | 172 | 2026-10-12 | 2026-10-21 |
| A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib Placebo, Elritercept - Myelofibrosis, Anemia | Phase 3 | Recruiting | Takeda | 324 | 2026-09-10 | 2026-10-01 |
| Tranexamic Acid for Anaemia Trial Tranexamic Acid 500 MG, Placebo - Anaemia | Phase 3 | Recruiting | London School of Hygiene and Tropical Medicine | 4000 | 2026-08-10 | 2026-08-17 |
| A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD) Mitapivat Matched Placebo, Mitapivat - Sickle Cell Disease | Phase 3 | Recruiting | Agios Pharmaceuticals, Inc. | 159 | 2026-07-21 | 2026-10-28 |
| Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease Lidocain, Placebo, Standard of care - Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Recruiting | Nantes University Hospital | 104 | 2026-07-03 | 2026-09-09 |
| A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently Pozelimab, Cemdisiran - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 35 | 2026-06-11 | 2026-08-05 |
| A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions Elritercept, Epoetin Alfa - Myelodysplastic Syndrome, Anemia | Phase 3 | Recruiting | Takeda | 300 | 2026-05-21 | 2026-10-19 |
| Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia Pharmacokinetic based dosage change, Pharmacokinetic dosing - Sickle Cell Disease (SCD) | Phase 2 / Phase 3 | Recruiting | Yves Pastore | 29 | 2026-02-03 | 2026-08-21 |
| Ferric Citrate in Iron Deficiency Anemia During Pregnancy Ferric citrate 210 mg, Ferrous fumarate 200 mg - Anemia | Phase 3 | Recruiting | Dhaka Medical College | 680 | 2026-02-01 | 2026-09-15 |
| Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease PCV21, 20vPCV - Sickle Cell Disease | Phase 3 | Recruiting | Sanofi | 100 | 2026-01-20 | 2026-04-15 |
| A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) AND017, ESA - Anemia Due to Chronic Kidney Disease | Phase 3 | Recruiting | Kind Pharmaceuticals LLC | 240 | 2025-12-03 | 2026-03-27 |
| Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study Monofer (iron isomaltoside 1000), Ferrous Sulfate - Peritoneal Dialysis, Anaemia | Phase 3 | Recruiting | Hull University Teaching Hospitals NHS Trust | 30 | 2025-11-13 | 2026-05-06 |
| A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia AND017 capsules, ESA - Anemia Due to Chronic Kidney Disease | Phase 3 | Recruiting | Kind Pharmaceuticals LLC | 300 | 2025-10-31 | 2026-03-27 |
| Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients LNP023 - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 12 | 2025-10-28 | 2026-08-07 |
| Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease Tocilizumab (RoActemra®, 20 mg/mL)., Placebo (NaCl 0.9%) - Sickle Cell Disease, Acute Chest Syndrome | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 130 | 2025-08-27 | 2026-06-24 |
| Co-administration of Calcium and Multiple Micronutrient Supplements for Maternal and Newborn Hemoglobin and Iron Status Concurrent multiple micronutrient and calcium supplementation, Separate multiple micronutrient and calcium supplementation - Anemia, Iron Deficiency | Phase 3 | Recruiting | Johns Hopkins Bloomberg School of Public Health | 3200 | 2025-08-25 | 2026-08-10 |
| A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia rilzabrutinib, placebo - Autoimmune Haemolytic Anaemia | Phase 3 | Recruiting | Sanofi | 90 | 2025-08-18 | 2026-10-20 |
| The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease Rilzabrutinib, Placebo - Sickle Cell Disease | Phase 3 | Recruiting | Sanofi | 192 | 2025-08-12 | 2026-10-15 |
| Choline and Iron Deficiency choline bitartrate, placebo drug - Pediatric Iron Deficiency, Anemia | Phase 2 / Phase 3 | Recruiting | University of Minnesota | 300 | 2025-08-11 | 2026-08-05 |
| Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis Danicopan - Paroxysmal Nocturnal Hemoglobinuria, PNH | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 6 | 2025-08-11 | 2025-12-23 |
Showing 20 of 46. Sign in to see all of them.
Anemia, Sickle Cell (13) · Anemia, Iron-Deficiency (8) · Hemoglobinuria, Paroxysmal (7) · Myelodysplastic Syndromes (4) · Atypical Hemolytic Uremic Syndrome (3) · Hematologic Diseases (3) · Iron Deficiencies (3) · Thalassemia (3) · beta-Thalassemia (3) · Acute Chest Syndrome (2) · Thrombotic Microangiopathies (2) · Vaso-Occlusive Crises (2) · Acute Kidney Injury (1) · Agnosia (1)
Hemic and Lymphatic Diseases (46) · Hematologic Diseases (43) · Anemia, Hemolytic (27) · Anemia, Hemolytic, Congenital (15) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (15) · Genetic Diseases, Inborn (14) · Hemoglobinopathies (14) · Bone Marrow Diseases (12) · Iron Metabolism Disorders (11) · Metabolic Diseases (11) · Nutritional and Metabolic Diseases (11) · Anemia, Hypochromic (8) · Iron Deficiencies (8) · Myelodysplastic Syndromes (7)
ferric derisomaltose (5) · Ferric Oxide, Saccharated (3) · Ferrosoferric Oxide (3) · ferrous sulfate (3) · Iron-Dextran Complex (2) · Sodium Chloride (2) · eculizumab (2) · iptacopan (2) · iron isomaltoside 1000 (2) · Ascorbic Acid (1) · Azacitidine (1) · Choline (1) · Danazol (1) · Epoetin Alfa (1) · Exercise (1)
Novartis Pharmaceuticals (4) · Sanofi (3) · Takeda (3) · Wuhan Createrna Science and Technology Co., Ltd (3) · AMAG Pharmaceuticals, Inc. (2) · Assistance Publique - Hôpitaux de Paris (2) · Kind Pharmaceuticals LLC (2) · Novo Nordisk A/S (2) · Regeneron Pharmaceuticals (2) · AHS Cancer Control Alberta (1) · Agios Pharmaceuticals, Inc. (1) · Alexion Pharmaceuticals, Inc. (1) · Auerbach Hematology Oncology Associates P C (1) · Baylor College of Medicine (1) · Brown University (1)
United States (21) · Italy (15) · United Kingdom (15) · France (14) · Spain (13) · Brazil (12) · Canada (12) · Germany (12) · Turkey (Türkiye) (11) · China (9) · Poland (9) · India (8) · Greece (7) · Hungary (7) · Japan (7)
Yusha Zhu, MD, PhD (2) · Alfa Muhihi, MD, MPH (1) · Amanda Palmer, PhD (1) · Andrea Pembe, MD, MMed, PhD, FCOG (1) · Ann-Marie Murtagh (1) · Blair Wylie, MD, MPH (1) · Christopher R Sudfeld, ScD, ScM (1) · Emily R Smith, ScD, MPH (1) · Gulab Fatima Rani, MBBS, PhD (1)
PMID 37254256, PMID 37945297, PMID 40517226, PMID 40832524, PMID 41257751, PMID 41857682, PMID 42767731
2023 (4), 2025 (1), U01HL157872 (1)